title: Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
abstract: Minimal change disease (MCD) in association with low-grade extra-nodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) (MALT lymphoma) is a rare clinicopathologic entity. We report a 68-year-old male who presented with nephrotic range proteinuria as the first manifestation of underlying MZL, confirmed with standard set of investigations. Being a steroid non-responder, he was treated with rituximab demonstrating a marked response with resolution of proteinuria. However, he relapsed after 3 months. Upon relapse, a combination of rituximab and bendamustine (R-Benda) was initiated achieving sustained resolution of proteinuria. No additional treatment was administered and the proteinuria has remained in remission for over a year.
authors.forename: Faisal
authors.initials: F
authors.lastname: Inayat
authors.forename: Jason K
authors.initials: JK
authors.lastname: Law
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Myers-Gurevitch
authors.forename: Surya V
authors.initials: SV
authors.lastname: Seshan
authors.forename: Alan S
authors.initials: AS
authors.lastname: Perlman
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000175:diagnosis; D003937:Diagnosis, Differential; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000175:diagnosis; D009402:Nephrosis, Lipoid / Q000175:diagnosis*; D011507:Proteinuria / Q000175:diagnosis; D000069283:Rituximab / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride